Imunoglobulina intravenosa e Síndrome de Sjögren
Palavras-chave:
Síndrome de Sjögren, imunoglobulina intravenosa, neuropatiaResumo
A síndrome de Sjögren (SS) é uma patologia auto-imune com
incidência e prevalência importantes, manifestações clínicas variadas e critérios diagnósticos bem definidos. Áreas como os seus
mecanismos fisiopatológicos e novas estratégias terapêuticas têm
merecido atenção crescente. A imunoglobulina intravenosa (IgIV)
está indicada para o tratamento de várias entidades nosológicas,
sendo crescente a investigação acerca dos seus mecanismos
de acção, nomeadamente sobre a actividade imunitária. O
seu espectro de indicações terapêuticas continua altamente
controverso mas tem vindo a expandir-se, sobretudo no âmbito
da auto-imunidade. Existem apenas alguns casos descritos de
utilização da IgIV no tratamento da SS, principalmente quando
se apresenta com manifestações neurológicas.
Apresentamos uma revisão da indicação do uso da IgIV na SS,
fazendo uma análise dos resultados de relatos de casos da sua
utilização, entretanto publicados. A IgIV parece ser uma opção
terapêutica a ter em conta na SS. Segundo o que se sabe, à
data, será uma opção terapêutica, de segunda linha, para os
casos com manifestações extraglandulares graves refractários
à terapêutica convencional.
Downloads
Referências
Goldman L, Ausiello D. Cecil Medicine. 23rd edition. Philadelphia: Saunders Elsevier 2008:2041-2045.
Fauci AS et al. Harrison’s principals of internal medicine, 17th ed. New York cGraw-Hill 2008:2107-2109.
Thanou-Stavraki A, James JA. Primary Sjögren Syndrome: Current and Prospective Therapies. Semin Arthritis Rheum 2008; 37(5):273-292.
Wiles CM et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Nuerosurg Psychiatry 2002:72:440-448.
Fox R. Sjögren’s syndrome. The Lancet 2005;366(9482):321-331.
Casals MR, Carrasco AG, Salazar JR, Alén JC, Franco JF. Enfermedades Autoinmunes sistémicas y reumatológicas. Masson Paris 2005:84-101.
Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjögren’s syndrome. Ann Rheum Dis 2004; 63:616-620.
Barendregt PJ et al. Involvement of the peripheral nervous system in primary Sjögren’s syndrome. Ann Rheum Dis 2001;60:876-881.
Coppo P et al. Primary Sjögren’s syndrome associated agranulocytosis: a benign disorder? Ann Rheum Dis 2003; 62:476-478.
Royer B et al. Lymphomas in Patients With Sjögren’s Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses. Blood 1997; 90(2):766-775.
Vitali C et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
Srinivason S, Slomovic AR. Sjögren syndrome. Compr Ophtalmol Update 2007; 8(4):205-212.
Woerkom JM et al. Safety and efficacy of leflunomide in primary Sjögren’s syndrome: a phase two pilot study. BMJ 2007;66:1026-1032.
Furst D E et al. Updated consensus statement on biological agents for the statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66:2-22.
Yamada S, Mori K, Matsuo K, Inukai A, Kawagashira Y, Sobue G. Interferon alfa treatment for Sjögren’s syndrome associated neuropathy. J Neurol Neurosurg Psychiatry 2005; 76:576-578.
Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren’s syndrome with low dose-human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Care and Research 2003 ;49(4):585-593.
Ramos-Casals M; Tzioufas AG; Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347-354.
Imbach P et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1(8232):1228-1231.
Orange J et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;S525-553.
Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clinical and Experimental Immunology 2005;142:1-11.
Gern JE. Antiinflamatory Activity of IVIG Mediated through the Inhitory FC Receptor. Official Journal of the American Academy of Pediatrics 2002; 110(2) 467-468.
Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98(10): 3136-3142.
Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, Bellon B, Kaveri S, Kazatchkine MD. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003; 24: S217–S221.
Janke AD, Yong VW. Impact of IVIG on the interaction between activated T cells and microglia. Neurological Research 2006; 28(3): 270-274.
Smith AJ et al. Neutralization of Muscarinic Receptor Autoantibodies by Intravenous Immunoglobulin in Sjögren Syndrome. Human Immunology 2005; 66(4): 411-416.
Nimmerjahn F e Ravetch JV. The antiinflamatory activity of IgG: the intravenous IgG paradox. JEM 2007; 204(1) 11-15.
Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmunity reviews. 2007 Mar; 6(4): 257-259
Elkayam O et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000;59:77.
Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjoögren’s syndrome. J Neurol Neurosurg Psychiatry 2006; 77: 967-969.
Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuropathy with Sjögren’s syndrome. Neurology 2003; 60:503-505.
Wolfe GI, Nations SP, Burns DK, Herbelin LL, Barohn RJ. Benefit of IVIG for long-standing ataxic sensory neuropathy with Sjogren’s syndrome. Neurology 2003;61:873.
Burns T, Quijano-Roy S, Jones HR. benefit of IVIG for long-standing ataxic sensory neuropathy with Sjögren’s syndrome. Neurology 2003;61:873.
Pascual J, Cid C, Berciano J. High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjogren’s syndrome. Neurology. 1998;51:650-651.
Levy Y, Uziel Y, Zandman GG, et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 2003;62:1221-1223.
Dupond JL, Gil H, De Waziere B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren’s syndrome, Am J Med
(1999):125.
Attout H, MArtre A, Guez S, Series C. Syndrome de Sjögren avec épilepsie et dysautonomie. La Revue de Médecine Interne 2005;26(2):141-144.
Taguchi Y et al. High-dose intravenous immunoglobulin in the treatment of sensory ataxic neuropathy with Sjögren’s syndrome: a case report. No To Shinkei 2004;56(5):421-424.
Zeuner RA, Schroeder JO, Schröder, Euler HH. Sucessful application of high dose intravenous immunoglobulins in Sjögren’s syndrome associated arthritis. Ann Rheum Dis 1995; 54: 936.
Amital H et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003;62:175-177
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
